Medication info
Nanubia Tablets 100 milligrams (Sitagliptin Hydrochloride Monohydrate)

Nanubia Tablets 100 milligrams (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›Strength being verified
Manufacturer / importer
Korea Hutech Pharmaceutical Co., Ltd.
Appearance
A bright brown, round, biconvex film-coated tablet.
Packaging
28 tablets/box [(14 tablets/PTPX2)]
Approval status
Active

MFDS item code 202101257 · Approved 2021.02.10 · Insurance code 649105270

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Korea Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood glucose control
View approved original text

This medication is used in conjunction with diet and exercise therapy to help control blood glucose levels in patients with type 2 diabetes. It can be used alone when starting diabetes treatment for the first time. However, if blood glucose control is insufficient with monotherapy, it can be combined with metformin. Additionally, it can also be used in combination for patients who find it difficult to control blood glucose with any single-agent therapy, such as sulfonylureas, thiazolidinediones, or insulin. In cases where combination therapy also fails to achieve adequate blood glucose control, this drug can be added to therapies combining sulfonylureas with metformin, thiazolidinediones with metformin, or insulin with metformin. It is effectively used in various situations to improve blood glucose control.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication is a drug that helps patients with diabetes control their blood glucose levels. While taking this medication, serious allergic reactions may occur infrequently. Conditions such as anaphylaxis, angioedema, and severe skin conditions have been reported, so if these symptoms occur, it is essential to stop taking the medication immediately and consult a doctor. Additionally, there is a risk of developing acute pancreatitis, which is inflammation of the pancreas, during treatment. It is crucial to inform healthcare providers immediately if abdominal pain, vomiting, or severe abdominal discomfort occurs. Patients with type 1 diabetes, diabetic ketoacidosis, or a hypersensitivity to this drug or its components should not take this medication. Patients with reduced kidney function may need to adjust dosages, and regular kidney function tests before and during treatment are advisable. In clinical trials, the incidence of hypoglycemia with this drug was similar to or slightly higher than that with placebo when used alone or in combination with other diabetes medications. Care should be taken especially when taken with insulin or sulfonylureas, as there is an increased risk of hypoglycemia. While taking this medication, side effects such as upper respiratory infections, nasopharyngitis, headaches, diarrhea, dyspepsia, etc., may occur. Severe joint pain or blistering skin conditions may occur, so it is necessary to notify a doctor immediately if these symptoms arise, and the medication should be discontinued if needed. Pregnant or breastfeeding women are advised against taking this medication, and safety in children and adolescents under 18 years of age has not been established. This medication has a low potential for drug interactions; however, caution may be required when used in combination with certain medications, so consultation with a physician or pharmacist is recommended. In the case of overdose, general emergency measures should be taken, and this drug can be partially removed by hemodialysis if necessary. Elderly patients may experience decreased kidney function, so dosage adjustments and monitoring of kidney function are necessary. This medication has been shown not to increase cardiovascular risk in cardiovascular safety studies.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory tract infection
  • headache
  • diarrhea
  • abdominal pain
Show 31 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • elevated liver enzymes
  • acute kidney failure
  • liver cancer
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • increased low-density lipoprotein
  • hyperglycemia
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air from entering, and keep it at a temperature between 1 and 30 degrees Celsius. Storing it this way helps to maintain the effectiveness of the medicine and prevents degradation.

Appearance and packaging

Appearance

A bright brown, round, biconvex film-coated tablet.

Package unit

28 tablets/box [(14 tablets/PTPX2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.